H. Schaefer and S. S. Renner, A three-genome phylogeny of Momordica (Cucurbitaceae) suggests seven returns from dioecy to monoecy and recent longdistance dispersal to Asia -Molecular Phylogenetics and Evolution, vol.54, pp.553-60, 2010.

T. W. Walters and . Decker-walters-ds--balsampear, Cucurbitaceae) -Journal of Economic and Taxonomic Botany, vol.42, pp.286-88, 1998.

N. Miniraj, K. P. Prasanna, and K. V. Peter, Bitter gourd Mornordicu app. genetic improvement of vegetable plants, pp.239-285, 1993.

. Decker-walters, DS -Cucurbits, sanskrit, and the indo-aryans -Economic Botany, vol.53, pp.98-112, 1999.

C. Giuliani, T. C. , and M. Bini, Micromorphology and anatomy of fruits and seeds of bitter melon (Momordica charantia L., Cucurbitaceae), vol.85, p.3490, 2016.

N. Ahmad, N. Hasan, Z. Ahmad, M. Zishan, S. Zohrameena et al., For traditional uses and pharmacological actions -The Journal of Drug Delivery Science and Technology, vol.6, pp.40-44, 2016.

M. Gupta, S. Sharma, A. Gautam, and L. Bhadauria-r--momordica-charantia, Karela): Nature's silent healer, International Journal of Pharmaceutical Sciences Review and Research, vol.11, pp.32-39, 2011.

S. Poolperm and W. Jiraungkoorskul, An update review on the anthelmintic activity of bitter gourd, Momordica charantia -Pharmacognosy Reviews, vol.11, issue.21, pp.31-34, 2017.

, Momordica charantiah t t p s : / / w w w . i t i s, Integrated Taxonomic Information System (ITIS), 2018.

, Momordica charantia. Consulté en janvier, 2019.

G. Froldi, Momordica charantia, nel trattamento fitoterapico dell'iperglicemia -Fitoterapia, 2006.

P. Pitchakarn, S. Suzuki, K. Ogawa, W. Pompimon, S. Takahashi et al., G1 arrest and apoptosis in androgen-dependent human

J. Kuguacin, Triterpenoid from Momordica charantia leaf -Cancer Letters, vol.306, pp.142-50, 2011.

J. B. Jini and D. , Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency -Asian Pacific, Journal of Tropical Disease, vol.3, issue.2, pp.93-102, 2013.

J. T. Efird, Y. M. Choi, S. W. Davies, S. Mehra, A. E. Katunga et al., Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes, International Journal of Environmental Research and Public Health, vol.11, issue.2, pp.2328-2373, 2014.

, National Nutrient Database for Standard Reference 1 Release -USDA, 2018.

R. I. Bakare and O. A. Magbagbeola, Akinwande AI and Okunowo OW -Nutritional and chemical evaluation of Momordica charantia, Journal of Medicinal Plants Research, vol.4, pp.2189-93, 2010.

R. Horax, N. Hettiarachchy, K. Over, C. P. Gbur, and E. , Extraction, fractionation and characterization of bitter melon seed proteins, Journal of Agricultural and Food Chemistry, vol.58, issue.3, pp.1892-97, 2010.

A. Upadhyay, P. Agrahari, and D. K. Singh, A review on salient pharmacological features of Momordica charantia, International Journal of Pharmacology, vol.11, issue.5, pp.405-418, 2015.

P. R. Dandawate, D. Subramaniam, P. Sb, S. Anant, and . Melon, Journal of Natural Medicines, vol.14, issue.2, pp.81-100, 2016.

M. E. Grossmann, N. K. Mizuno, M. L. Dammen, T. Schuster, R. A. Cleary et al., Acid inhibits breast cancer proliferation by means of an oxidationdependent mechanism -Cancer Prevention Research, vol.2, pp.879-86, 2009.

M. A. Alam, R. Uddin, N. Subhan, M. M. Rahman, P. Jain et al., Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome, Journal of Lipids, vol.496169, p.18, 2015.

J. Singh, E. Cumming, and G. Manoharan, Kalasz H et Adeghate E -Medicinal chemistry of the anti-diabetic effects of Momordica charantia: Active constituents and modes of actions -The Open, Medicinal Chemistry Journal, vol.5, issue.2, pp.70-77, 2011.

J. Kubola and S. Siriamornpun, Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro -Food Chemistry, vol.110, pp.881-90, 2008.

R. Horax, N. Hettiarachchy, and P. Chen, Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (Immature, Mature, and Ripe, Journal of Agricultural and Food Chemistry, vol.58, issue.7, pp.4428-4461, 2010.

J. Ahamad, S. Amin, S. Mir, and . Linn, Cucurbitaceae): Review on Phytochemistry and Pharmacology -Research Journal of Phytochemistry, vol.11, pp.53-65, 2017.

J. Q. Liu, J. C. Chen, C. F. Wang, and M. H. Qiu, New cucurbitane triterpenoids and steroidal glycoside from Momordica charantia -Molecules, vol.14, pp.4804-4817, 2009.

Y. Kimura, T. Akihisa, N. Yuasa, M. Ukiya, T. Suzuki et al., Momordica charantia -Journal of Natural Products, vol.68, issue.5, pp.807-816, 2005.

T. Murakami, A. Emoto, H. Matsuda, . Yoshikawa-m--medicinal-foodstuffs, and . Xxi, Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of, Japanese Momordica charantia L. -Chemical and Pharmaceutical Bulletin, vol.49, issue.1, pp.54-63, 2001.

N. X. Nhiem, P. V. Kiem, C. V. Minh, N. K. Ban, N. X. Cuong et al., Glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia -Chemical and Pharmaceutical Bulletin, vol.58, pp.720-724, 2010.

G. J. Handa, M. Singh, L. Sharma, A. Kaul, and R. Zafar, Hypoglycemic principle of Momordica charantia seeds, Indian Journal of Natural Products and Resources, vol.6, pp.16-19, 1990.

C. I. Chang, C. R. Chen, Y. W. Liao, H. L. Cheng, C. Yc et al., Momordica charantia -Journal of Natural Products, vol.69, issue.8, pp.1168-71, 2006.

C. I. Chang, C. R. Chen, Y. W. Liao, H. L. Cheng, Y. C. Chen et al., Cucurbitanetype triterpenoids from the stems of Momordica charantia, Journal of Natural Products, vol.71, issue.8, pp.1327-1357, 2008.

J. Pitipanapong, S. Chitprasert, M. Goto, W. Jiratchariyakul, M. Sasaki et al., New approach for extraction of charantin from Momordica charantia with pressurized liquid extraction -Separation and Purification Technology, vol.52, 2007.

J. C. Chen, W. Q. Liu, L. Lu, M. H. Qiu, Y. T. Zheng et al., cucurbitane triterpenoids from Momordica charantia -Phytochemistry, vol.70, issue.1, pp.133-173, 2009.

S. Nakamura, T. Murakami, J. Nakamura, H. Kobayashi, H. Matsuda et al., Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka -Chemical and Pharmaceutical Bulletin, vol.54, pp.1545-50, 2006.

K. Raina, D. Kumar, and R. Agarwal, Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy -Seminars in Cancer Biology, pp.116-145, 2016.

T. Akihisa, N. Higo, H. Tokuda, M. Ukiya, H. Akazawa et al., Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects, Journal of Natural Products, vol.70, issue.8, pp.1233-1242, 2007.

P. C. Hsiao, C. C. Liaw, S. Y. Hwang, H. L. Cheng, L. J. Zhang et al., Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia, Journal of Agricultural and Food Chemistry, vol.6, issue.11, pp.22979-86, 2013.

S. Desai and P. Tatke, An important lead compound from Momordica charantia for the treatment of diabetes, Journal of Pharmacognosy and Phytochemistry, vol.3, issue.6, pp.163-66, 2015.

M. J. Tan, J. M. Ye, N. Turner, C. Hohnen-behrens, C. Q. Ke et al., Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway, Chemistry & Biology, vol.15, issue.3, pp.263-73, 2008.

J. C. Chen, L. Lu, X. M. Zhang, L. Zhou, L. Zr et al., Eight new cucurbitane glycosides, kuguaglycosides A -H, from the root of Momordica charantia L. -Helvetica chimica acta, vol.91, pp.920-949, 2008.

G. T. Zhao, J. Q. Liu, Y. Y. Deng, H. Z. Li, J. C. Chen et al., Cucurbitane-type triterpenoids from the stems and leaves of Momordica charantia -Fitoterapia, vol.95, pp.75-82, 2014.

B. H. Cheng, J. C. Chen, J. Q. Liu, L. Zhou, and M. Qiu, Type Triterpenoids from Momordica charantia -Helvetica chimie acta, vol.96, pp.1111-1131, 2013.

H. Matsuda, S. Nakamura, T. Murakami, M. Yoshikawa, ;. et al., Structure of new cucurbitane-type triterpenes and glycosides, karavilagenins, vol.71, pp.331-372, 2007.

Z. Haixia, Z. Xiaozuo, W. Yawei, L. Mancanq, and H. Zhide, Analysis of vicine in bitter melon samples by polyglycol-C8 solid phase with high performance liquid chromatography, Chinese Journal of Analytical Chemistry, vol.3, pp.408-108, 2004.

A. Braca, T. Siciliano, D. 'arrigo, M. Germanò, and M. , Chemical composition and antimicrobial activity of Momordica charantia seed essential oil -Fitoterapia, vol.79, pp.123-128, 2008.

Y. Guo-jie, L. Bao-yuan, J. Shan-wei, Q. Rui-qing, and Y. , Primary structure of ?-momorcharin, a ribosome-inactivating protein from the seeds of Momordica charantia Linn (Cucurbitaceae) -Chinese Journal of Chemistry, vol.17, pp.658-73, 1999.

Y. L. Li, K. Ma, H. M. Wu, G. J. Ye, J. Sw et al., Structure determination of glycopeptide of p-momorcharin -Chinese Journal of Chemistry, vol.17, pp.516-541, 1999.

F. Zhang, W. W. Li, H. W. Yeung, S. Chen, Y. Wang et al., Crystals of ?-momorcharin. A new ribosome-inactivating protein, Journal of Molecular Biology, vol.214, issue.3, pp.625-631, 1990.

J. P. Xiong, Z. X. Xia, L. Zhang, G. J. Ye, J. Sw et al., Crystallization and preliminary crystallographic study of ?-momorcharin, Journal of Molecular Biology, vol.238, issue.2, pp.284-289, 1994.

Y. R. Yuan,

J. P. Xiong and Z. Xia, The determination and refinement of threedimensional structure of ?-momorcharin at 2.4Å resolution -Chinese Chemical Letters, vol.6, pp.1053-1057, 1995.

Z. Feng, W. W. Li, and H. W. Yeung, Crystals of ?-Momorcharin a new ribosomeinactivating protein, vol.214, pp.625-651, 1990.

S. Wang, Y. Zheng, J. Yan, Z. Zhu, Z. Wu et al., ?-momorcharin: a ribosomeinactivating protein from Momordica charantia, possessing DNA cleavage properties -Protein & Peptide Letters, vol.20, pp.1257-63, 2013.

S. Lee-huang, P. L. Huang, P. L. Nara, H. C. Che, H. F. Kung et al., MAP 30: a new inhibitor of HIV-l infection and replication -FEBS Letters, vol.272, pp.12-20, 1990.

S. Rybak, J. Lin, D. Newton, H. Kung, A. Monks et al., In-vitro antitumor-activity of the plant ribosome-inactivating proteins map-30 and gap-31, International Journal of Oncology, vol.5, issue.5, pp.1171-1177, 1994.

L. D. Jones, P. Panglolia, H. B. Krishnan, and D. Vp, BG-4, a novel bioactive peptide from Momordica charantia, inhibits lipopolysaccharide-induced inflammation in THP-1 human macrophages -Phytomedicine, vol.42, pp.226-258, 2018.

D. Vp and H. B. Krishnan, BG-4, a novel anticancer peptide from bitter gourd (Momordica charantia), promotes apoptosis in human colon cancer cells -Scientific Reports, vol.6, p.33532, 2016.

Z. Ahmad, K. F. Zamhuri, A. Yaacob, C. H. Siong, M. Selvarajah et al., In vitro anti-diabetic activities and chemical analysis of polypeptide-k and oil isolated from seeds of M. charantia (bitter gourd), Molecules, vol.17, issue.8, pp.9631-9671, 2012.

M. Kobori, H. Nakayama, K. Fukushima, M. Ohnishi-kameyama, H. Ono et al., Bitter gourd suppresses lipopolysaccharide-induced inflammatory responses, Journal of Agricultural and Food Chemistry, vol.56, issue.11, pp.4004-4015, 2008.

S. Gupta, B. Raychaudhuri, S. Banerjee, B. Das, S. Mukhopadhaya et al., Momordicatin purified from fruits of Momordica charantia is effective to act as a potent antileishmania agent, Parasitology International, vol.59, issue.2, pp.192-199, 2010.

N. X. Nhiem, P. H. Yen, N. T. Ngan, T. H. Quang, P. V. Kiem et al., Inhibition of nuclear transcription factor-?B and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia, Journal of Medicinal Food, vol.15, issue.4, pp.369-77, 2012.

J. Y. Lin and C. Tang, loquat, mulberry, and bitter melon juices exhibit prophylactic effects on LPS-induced inflammation using murine peritoneal macrophages, Food Chemistry, vol.107, issue.4, pp.1587-96, 2008.

P. V. Nerurkar, L. M. Johns, L. M. Buesa, G. Kipyakwai, E. Volper et al., Momordica charantia (bitter melon) attenuates highfat diet-associated oxidative stress and neuroinflammation, Journal of Neuroinflammation, vol.8, p.64, 2011.

C. Y. Chao, P. J. Sung, W. Wh, and Y. H. Kuo, Anti-inflammatory effect of Momordica charantia in sepsis mice -Molecules, vol.19, pp.12777-88, 2014.

M. Ullah, M. Showkat, U. N. Ahmed, S. Islam, and N. Absar, Evaluation of Momordica charantia L. fruit extract for analgesic and anti-inflammatory activities using in vivo assay, Research Journal of Medical Plant Research, vol.2012, issue.3, pp.236-280

M. Manabe, R. Takenaka, T. Nakasa, and O. Okinaka, Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd) -Bioscience, Biotechnology, and Biochemistry, vol.67, issue.12, pp.2512-2519, 2003.

D. O. Brandao, G. P. Guimaraes, R. L. Santos, F. J. Junior, D. Silva et al., Model analytical development for physical, chemical, and biological characterization of Momordica charantia vegetable drug, Journal of Analytical Methods in Chemicals, issue.3, pp.1-15, 2016.

M. Gupta, S. Sharma, and R. Bhadauria, In vitro efficacy of Momordica charantia extracts against phytopathogenic fungi Fusarium oxysporum, Journal of Biopesticides, vol.9, issue.1, pp.8-22, 2016.

S. Wang, Y. Zheng, F. Xiang, S. Li, and G. Yang, Antifungal activity of Momordica charantia seed extracts toward the pathogenic fungus Fusarium solani L, Journal of food and drug analysis, vol.24, issue.4, pp.881-87, 2016.

A. S. Bourinbaiar and . Lee-huang, S -The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against Herpes simplex virus in vitro -Biochemical and Biophysical Research Communications, vol.219, pp.923-932, 1996.

J. M. Fan, Q. Zhang, J. Xu, S. Zhu, T. Ke et al., Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon, Molecular Biology Reports, vol.36, issue.2, pp.381-389, 2009.

M. Puri, I. Kaur, R. K. Kanwar, R. C. Gupta, A. Chauhan et al., Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy -Current Molecular Medicine, vol.9, pp.1080-94, 2009.

J. C. Chen, W. Q. Liu, L. Lu, M. H. Qiu, Y. T. Zheng et al., cucurbitane triterpenoids from Momordica charantia -Phytochemistry, vol.70, issue.1, pp.133-173, 2009.

J. Chen, R. Tian, M. Qiu, L. Lu, Y. Zheng et al., Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia -Phytochemistry, vol.69, pp.1043-1051, 2008.

E. Ye?ilada, G. I. Shibata, and H. , Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity, Journal of Ethnopharmacology, vol.66, issue.3, pp.289-93, 1999.

M. Raish, A. Ahmad, M. A. Ansari, K. M. Alkharfy, F. I. Aljenoobi et al., Momordica charantia polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF-kB signaling pathway inhibition, International Journal of Biological Macromolecules, vol.111, pp.193-99, 2018.

I. Gürbüz, C. Akyüz, Y. E. Sener, and B. , Anti-ulcerogenic effect of Momordica charantia L. fruits on various ulcer models in rats, Journal of Ethnopharmacology, vol.71, issue.1-2, pp.77-82, 2000.

S. Alam, M. Asad, A. Sm, and P. Vs, Antiulcer activity of methanolic extract of Momordica charantia L. in rats, Journal of Ethnopharmacology, vol.123, issue.3, pp.464-473, 2009.

G. I. Olasehinde, O. Ojurongbe, A. O. Adeyeba, O. E. Fagade, N. Valecha et al., In vitro studies on the sensitivity pattern of Plasmodium falciparum to anti-malarial drugs and local herbal extracts, Malaria Journal, vol.13, p.63, 2014.

P. R. Dandawate, D. Subramaniam, P. Sb, S. Anant, and . Melon, Journal of Natural Medicines, vol.14, issue.2, pp.81-100, 2016.

A. Ghosh, N. Chowdhury, and G. Chandra, Plant extracts as potential mosquito larvicides -Indian Journal of Medical Research, vol.135, pp.581-98, 2012.

V. C. Brennan, C. M. Wang, and W. H. Yang, Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, et insulin-like growth factor type 1 receptor/ RAC-? Serine/Threonine-Protein Kinase signaling, Journal of Medicinal Food, vol.15, issue.4, pp.325-359, 2012.

P. Pitchakarn, K. Ogawa, S. Suzuki, S. Takahashi, M. Asamoto et al., Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo -Cancer Science, vol.101, pp.2234-2274, 2010.

S. D. Xiong, K. Yu, X. H. Liu, L. H. Yin, A. Kirschenbaum et al., Inactivating Proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells, Journal International du Cancer, vol.125, issue.4, pp.774-82, 2009.

P. Pitchakarn, S. Ohnuma, K. Pintha, and W. Pompimon, Ambudkar SV and Limtrakul P -Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance -The Journal of Nutritional Biochemistry, vol.23, pp.76-84, 2012.

C. Shobha, P. Vishwanath, M. Suma, A. Prashant, C. Rangaswamy et al., In vitro anti-cancer activity of ethanolic extract of Momordica charantia on cervical and breast cancer cell lines, International Journal of Health & Allied Sciences, vol.4, issue.4, pp.210-227, 2015.

H. Kai, E. Akamatsu, E. Torii, H. Kodama, C. Yukizaki et al., Identification of a bioactive compound against adult T-cell leukaemia from bitter gourd seeds -Plants, vol.3, pp.18-26, 2014.

K. Suknuntha, T. Thita, P. P. Togarrati, P. Ratanachamnong, P. Wongtrakoongate et al., Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines, International Journal of Hematology, vol.105, issue.2, pp.196-205, 2017.

J. Zhang, Y. Huang, T. Kikuchi, H. Tokuda, N. Suzuki et al., Cucurbitane triterpenoids from the leaves of Momordica charantia, and their cancer chemopreventive effects and cytotoxicities -Chemistry Biodiversity, vol.9, pp.428-468, 2012.

Y. Sun, P. L. Huang, J. J. Li, Y. Q. Huang, L. Zhang et al., HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus -Biochemical and Biophysical Research Communications, vol.287, pp.983-94, 2001.

C. R. Chen, Y. W. Liao, L. Wang, Y. H. Kuo, H. J. Liu et al., Cucurbitane triterpenoids from Momordica charantia and their cytoprotective activity in tert-butyl hydroperoxide-induced hepatotoxicity of HepG2 cells -Chemical and Pharmeucital Bulletin, vol.58, pp.1639-1681, 2010.

X. Fan, L. He, Y. Meng, G. Li, L. L. Meng et al., two ribosomeinactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells, Molecular Medicine Report, vol.11, issue.5, pp.3553-3561, 2015.

S. Yasuda, S. Yogosawa, Y. Izutani, Y. Nakamura, H. Watanabe et al., Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen speciesdependent mechanism in human colon adenocarcinoma SW480 cells -Molecular Nutrition Food Research, vol.54, pp.559-65, 2009.

N. Muhammad, R. Steele, T. S. Isbell, N. Philips, and R. B. Ray, Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death -Oncotarget, vol.8, pp.66226-66262, 2017.

R. J. Zhuo, F. Wang, X. H. Zhang, J. J. Zhang, J. Xu et al., Eleostearic Acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling, Molecular Medicine Reports, vol.9, issue.3, pp.993-1001, 2014.

J. Q. Cao, Y. Zhang, J. M. Cui, and Y. G. Zhao, Two new cucurbitane triterpenoids from Momordica charantia L, Chinese Chemical Letters, vol.22, issue.5, pp.583-86, 2011.

R. C. Agrawal and T. Beohar, Chemopreventive and anticarcinogenic effects of Momordica charantia extract -Asian Pacific Journal of Cancer Prevention, vol.11, pp.371-376, 2010.

P. Pitchakarn, S. Suzuki, K. Ogawa, W. Pompimon, S. Takahashi et al., Triterpeniod from Momordica charantia Leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3 -Food and Chemical Toxicology, vol.50, pp.840-847, 2012.

R. B. Ray, A. Raychoudhuri, R. Steele, and P. Nerurkar, Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis -Cancer Research, vol.70, pp.1925-1956, 2010.

M. ?lhan, I. E. Bolat, ?. Süntar, K. Köklü, H. et al., Topical application of olive oil macerate of Momordica charantia L. promotes healing of excisional and incisional wounds in rat buccal mucosa -Archives of Oral Biology, vol.60, pp.1708-1721, 2015.

A. Piskin, B. Z. Altunkaynak, G. Tumentemur, S. Kaplan, Y. Ob et al., The beneficial effects of Momordica charantia (bitter gourd) on wound healing of rabbit skin -The Journal of Dermatological Treatment, vol.60, pp.1708-1721, 2014.

S. L. Teoh, A. A. Latiff, and S. Das, The effect of topical extract of Momordica charantia (bitter gourd) on wound healing in nondiabetic rats and in rats with diabetes induced by streptozotocin -Clinical and Experimental Dermatology, vol.34, pp.815-837, 2009.

L. Monnier--diabétologie, , 2014.

, -Fédération Internationale du Diabète -Atlas 8ème édition 2017 -Consultation, 2018.

, World Health Organization -Global Health Estimates, 2016.

S. H. Ley, O. Hamdy, and M. V. Hu, FB -Prevention and management of type 2 diabetes: dietary components and nutritional strategies -The Lancet, vol.383, pp.1999-2007, 2014.

F. Ng and N. Wareham, EPIC-Interact study: a study of the interplay between genetic and lifestyle behavioral factors on the risk of type 2 diabetes in european populations -Current Nutrition Reports, vol.3, pp.355-63, 2014.

J. Salas-salvadó, M. Bulló, N. Babio, M. Á. Martínez-gonzález, N. Ibarrola-jurado et al., Investigators -Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial -Diabetes Care, vol.34, pp.14-23, 2011.

R. Huo, T. Du, Y. Xu, W. Xu, X. Chen et al., Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis, European Journal of Clinical Nutrition, vol.69, issue.11, pp.1200-1208, 2015.

R. Goldenberg and Z. Punthakee, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee -Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome, Canadian Journal of Diabetes, vol.37, issue.1, pp.369-72, 2013.

, American Diabetes Association -Classification and diagnosis of diabetes: standards of medical care in diabetes -Diabetes Care, vol.41, pp.13-27, 2018.

A. Lim, Diabetic nephropathy -complications and treatment, International Journal of Nephrology and Renovascular Disease, vol.7, pp.361-81, 2014.

G. Danaei, C. M. Lawes, S. Vander-hoorn, M. Cj, and M. Ezzati, Global and regional mortality from ischaemic heart disease and stroke attributable to higherthanoptimum blood glucose concentration: comparative risk assessment -Lancet, vol.368, pp.1651-1660, 2006.

N. Sarwar, T. Aspelund, G. Eiriksdottir, R. Gobin, S. R. Seshasai et al., Danesh J and Gudnason V -Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik Prospective Study and systematic review, PLoS Med, vol.7, issue.5, p.1000278, 2010.

I. Martín-timón, C. Sevillano-collantes, A. Segura-galindo, and . Del-cañizo, Gómez FJ -Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?, World Journal of Diabetes, vol.5, issue.4, pp.444-70, 2014.

A. R. Saltiel and C. R. Kahn, Insulin signalling and the regulation of glucose and lipid metabolism -Nature, vol.414, pp.799-806, 2001.

N. Bashan, J. Kovsan, I. Kachko, H. Ovadia, and A. Rudich, Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species -Physiological Reviews, vol.89, pp.27-71, 2009.

E. Harmel, Rôle et régulation de la protéine kinase AMPK au niveau intestinal -Médecine humaine et pathologie -Thèse de l'université Claude Bernard Lyon, pp.1-2012

B. A. Hemmings and D. Restuccia, Akt pathway -Cold Spring Harbor Perspectives, vol.4, p.11189, 2012.

B. D. Manning, A. Toker, and . Signaling, , vol.169, pp.381-405, 2017.

, White MF -IRS proteins and the common path to diabetes, The American Journal of Physiology-Endocrinology and Metabolism, vol.283, issue.3, pp.413-435, 2002.

S. H. Um, D. 'alessio, D. Thomas, and G. , Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1 -Review Cell Metabolism, vol.3, pp.393-402, 2006.

K. Egawa, H. Maegawa, S. Shimizu, K. Morino, Y. Nishio et al., Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and fao hepatoma cells, The Journal of Biological Chemistry, vol.276, issue.13, pp.10207-10218, 2001.

K. Shi, K. Egawa, H. Maegawa, T. Nakamura, S. Ugi et al., Protein-tyrosine phosphatase 1B associates with insulin receptor and negatively regulates insulin signaling without receptor internalization, Journal of Biochemistry, vol.136, issue.1, pp.89-96, 2004.

L. V. Ravichandran, D. L. Esposito, C. J. Quon, and M. , Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin, Journal of Biological Chemistry, vol.276, issue.5, pp.3543-3552, 2001.

B. Barbara, . Kahn, and S. Jeffrey, Flier -Obesity and insulin resistance, Journal of Clinical Investigation, vol.106, issue.4, pp.473-81, 2000.

L. Serra-majem, R. B. Estruch, and R. , Scientific evidence of interventions using the Mediterranean diet: a systematic review -Nutrition Reviews, vol.64, pp.27-47, 2006.

A. S. Lihn, S. B. Pedersen, and B. Richelsen, Adiponectin: action, regulation and association to insulin sensitivity -Obesity Reviews, vol.6, pp.13-21, 2005.

C. N. Lumeng, S. M. Deyoung, J. L. Bodzin, and A. R. Saltiel, Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity -Diabetes, vol.56, pp.16-23, 2007.

S. P. Weisberg, D. Mccann, M. Desai, M. Rosenbaum, and J. Ferrante, AW -Obesity is associated with macrophage accumulation in adipose tissue, Journal of Clinical Investigation, vol.112, issue.12, pp.1796-808, 2003.

H. Xu, G. T. Barnes, Q. Yang, G. Tan, D. Yang et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, Journal of Clinical Investigation, vol.112, issue.12, pp.1821-1851, 2003.

T. Kawai and S. Akira, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity -Immunity, vol.34, pp.637-50, 2011.

H. Shi, M. V. Kokoeva, K. Inouye, and I. Tzameli, Yin H and Flier JS -TLR4 links innate immunity and fatty acid-induced insulin resistance, Journal of Clinical Investigation, vol.116, issue.11, pp.3015-3040, 2006.

T. Liu, L. Zhang, J. D. Sun, and S. C. , NF-?B signaling in inflammation -Signal Transduction and Targeted Therapy, vol.2, p.17023, 2017.

S. I. Itani, N. B. Ruderman, F. Schmieder, and G. Boden, Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha -Diabetes, vol.51, pp.2005-2016, 2002.

C. K. Glass and J. M. Olefsky, Inflammation and lipid signaling in the etiology of insulin resistance -Cell Metabolism, vol.15, pp.635-680, 2012.

C. K. Glass and J. M. Olefsky, Inflammation and lipid singling in the ethnology of insuline resistance -Cell Metabolism, vol.15, pp.635-680, 2012.

H. J. Forman and M. Torres, Reactive oxygen species and cell signaling respiratory burst in macrophage signaling -American Journal of Respiratory and Critical Care Medicine, vol.166, pp.4-8, 2002.

U. Ozcan, Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi et al., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes -Science, vol.306, pp.457-61, 2004.

H. Cao, Adipocytokines in obesity and metabolic disease, Journal of Endocrinology, vol.220, issue.2, pp.47-59, 2014.

S. Schenk, M. Saberi, and J. M. Olefsky, Insulin sensitivity: modulation by nutrients and inflammation, Journal of Clinical Investigation, vol.118, issue.9, pp.2992-3002, 2008.

. Dali-youcef, N -Lessons learned from metabolic inflammation in insulin resistance development -Medicine of Metabolic Diseases, vol.9, pp.279-91, 2015.

K. Sun, C. M. Kusminski, and P. M. Scherer, Adipose tissue remodeling and obesity, Journal of Clinical Investigation, vol.121, issue.6, pp.2094-2101, 2011.

A. B. Molofsky, F. Van-gool, H. E. Liang, S. J. Van-dyken, J. C. Nussbaum et al., Interleukin-33 and IFN-? counter-regulate Group 2 innate lymphoid cell activation during immune perturbation -Immunity, vol.43, pp.161-74, 2015.

J. R. Brestoff, B. S. Kim, S. A. Saenz, R. R. Stine, L. A. Monticelli et al., Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity -Nature, vol.519, pp.242-248, 2015.

M. E. Trujillo and P. E. Scherer, Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome, Journal of Internal Medicine, vol.257, issue.2, pp.167-75, 2005.

D. Foster, the regulator of fatty acid synthesis and oxidation, vol.122, pp.1958-59, 2012.

T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki et al., Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome, Journal of Clinical Investigation, vol.116, issue.7, pp.1784-92, 2006.

P. A. Lochhead, I. P. Salt, K. S. Walker, D. G. Hardie, and C. Sutherland, 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase, Diabetes, vol.49, issue.6, pp.896-903, 2000.

T. P. Combs, A. H. Berg, S. Obici, P. E. Scherer, and L. Rossetti, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, Journal of Clinical Investigation, vol.108, issue.12, pp.1875-81, 2001.

A. H. Berg, T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nature Medecine, vol.7, issue.8, pp.947-53, 2001.

J. T. Treebak, S. Glund, A. Deshmukh, D. K. Klein, Y. C. Long et al., AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits -Diabetes, vol.55, pp.2051-2059, 2006.

N. Maeda, I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda et al., Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 -Nature Medicine, vol.8, pp.731-738, 2002.

Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda et al., Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity -Biochemical and Biophysical Research Communications, vol.257, pp.79-83, 1999.

S. Li and H. J. Shin, Ding EL and van Dam RM -Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis, Journal of the American Medical Association, vol.302, issue.2, pp.179-88, 2009.

J. M. Friedman and J. L. Halaas, Leptin and the regulation of body weight in mammals -Nature, vol.395, pp.763-70, 1998.

M. W. Schwartz, S. C. Woods, D. Porte, R. J. Seeley, and D. G. Baskin, Central nervous system control of food intake -Nature, vol.404, pp.661-71, 2000.

Y. Minokoshi, Y. B. Kim, O. D. Peroni, L. G. Fryer, C. Müller et al., Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase -Nature, vol.415, pp.339-382, 2002.

P. Cohen, M. Miyazaki, N. D. Socci, A. Hagge-greenberg, W. Liedtke et al., Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss -Science, vol.297, pp.240-243, 2002.

S. L. Dunn, M. Björnholm, S. H. Bates, Z. Chen, M. Seifert et al., Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppres-sor of cytokine signaling 3 -Molecular Endocrinology, vol.19, pp.925-963, 2005.

J. M. Zabolotny, K. K. Bence-hanulec, A. Stricker-krongrad, F. Haj, Y. Wang et al., Kahn BB and Neel BG -PTP1B regulates leptin signal transduction in vivo -Developmental Cell, vol.2, pp.489-95, 2002.

M. Maffei, J. Halaas, E. Ravussin, R. E. Pratley, G. H. Lee et al., Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects -Nature Medicine, vol.1, pp.1155-61, 1995.

C. Grunfeld, C. Zhao, J. Fuller, A. Pollack, A. Moser et al., Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters, Journal of Clinical Investigation, vol.97, issue.9, pp.2152-2159, 1996.

L. Cava, A. Matarese, and G. , The weight of leptin in immunity, Nature Reviews Immunology, vol.4, issue.5, pp.371-380, 2004.

C. M. Steppan, S. T. Bailey, S. Bhat, E. J. Brown, R. R. Banerjee et al., The hormone resistin links obesity to diabetes -Nature, vol.409, pp.307-319, 2001.

R. R. Banerjee, S. M. Rangwala, J. S. Shapiro, A. S. Rich, B. Rhoades et al., Regulation of fasted blood glucose by resistin, Science, vol.303, issue.5661, pp.1195-1203, 2004.

R. Palanivel and G. Sweeney, Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin -FEBS Letters, vol.579, pp.5049-54, 2005.

M. J. Vázquez, C. R. González, L. Varela, R. Lage, S. Tovar et al., Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion -Endocrinology, vol.149, pp.4534-4577, 2008.

M. S. Burnett, J. M. Devaney, R. J. Adenika, L. R. Howard, and B. V. , Cross-sectional associations of resistin, coronary heart disease, and insulin resistance, Journal of Clinical Endocrinology and Metabolism, vol.91, issue.1, pp.64-72, 2006.

C. Heidemann, Q. Sun, R. M. Van-dam, J. B. Meigs, C. Zhang et al., Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women -Annals of Internal Medicine, vol.149, pp.307-323, 2008.

M. S. Jamaluddin, M. S. Weakley, Q. Yao, and C. , functional roles and therapeutic considerations for cardiovascular disease, vol.165, pp.622-654, 2012.

M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar et al., Resistin is an inflammatory marker of atherosclerosis in humans -Circulation, vol.111, pp.932-941, 2005.

J. Hsieh, A. A. Hayashi, and J. Webb, Adeli K -Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity -Atherosclerosis Supplements, vol.9, pp.7-13, 2008.

B. Vergès, Pathophysiology of diabetic dyslipidaemia: where are we? -Diabetologia, vol.58, pp.886-99, 2015.

F. Caballero, A. Fernández, D. Lacy, A. M. Fernández-checa, J. C. et al., C -Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH -The Journal of Hepatology, vol.50, pp.789-96, 2009.

S. Lally, C. Y. Tan, D. Owens, and G. Tomkin, RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein -Diabetologia, vol.49, pp.1008-1024, 2006.

O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli et al., metabolic syndrome, and risk of coronary artery disease -The Journal of Lipid Research, vol.44, pp.2374-81, 2003.

, De Fronzo RA -Pathogenesis of type 2 diabetes mellitus -The Medical Clinics of North America, vol.88, pp.787-835, 2004.

D. Prato, S. Marchetti, P. Bonadonna, and R. C. , Phasic insulin release and metabolic regulation in type 2 diabetes -Diabetes, vol.51, pp.109-125, 2002.

S. F. Grant, G. Thorleifsson, I. Reynisdottir, R. Benediktsson, A. Manolescu et al., Kong A and Stefansson K -Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes, Nature Genetics, vol.38, issue.3, pp.320-323, 2006.

M. Prentki, E. Joly, W. El-assaad, and R. , CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes -Diabetes, vol.51, pp.405-418, 2002.

P. Westermark, A. A. Westermark, and G. T. , Islet amyloid polypeptide, islet amyloid, and diabetes mellitus, vol.91, pp.795-826, 2011.

R. P. Robertson, Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes, Journal of Biological Chemistry, vol.279, issue.41, pp.42351-42355, 2004.

S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini et al., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) -Diabetologia, vol.55, pp.1577-96, 2012.

J. Tuomilehto, J. Lindström, J. G. Eriksson, T. T. Valle, H. Hämäläinen et al., Diabetes Prevention Study Group -Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance -The, New England Journal of Medicine, vol.344, issue.18, pp.1343-50, 2001.

I. M. Stratton, A. I. Adler, H. A. Neil, D. R. Matthews, S. E. Manley et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, British Medical Journal, vol.321, issue.7258, pp.405-417, 2000.

-. Ukpds-group and . Prospective, Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients -Metabolism, vol.39, pp.905-917, 1990.

L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon et al., Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, Journal of the American Medical Association, vol.295, issue.14, pp.1681-1688, 2006.

F. S. Atkinson, K. Foster-powell, and . Brand-miller, JC -International tables of glycemic index and glycemic load values: 2008 -Diabetes Care, vol.31, pp.2281-83, 2008.

M. Chandalia, A. Garg, D. Lutjohann, V. Bergmann, K. et al., Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus -The New England, Journal of Medicine, vol.342, issue.19, pp.1392-1400, 2000.

H. Buchwald, Y. Avidor, E. Braunwald, M. D. Jensen, W. Pories et al., Bariatric surgery: a systematic review and meta-analysis, Journal of the American Medical Association, vol.292, issue.14, pp.1724-1761, 2004.

A. C. Keller, J. Ma, A. Kavalier, K. He, A. Brillantes et al., Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro -Phytomedicine, vol.19, pp.32-37, 2011.

D. Sathishsekar and S. Subramanian, Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats -Biological and Pharmaceutical Bulletin, vol.28, pp.978-83, 2005.

I. Ahmed, E. Adeghate, E. Cummings, A. K. Sharma, and J. Singh, Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocininduced diabetes mellitus in rat -Molecular and Cellular Biochemistry, vol.261, pp.63-70, 2004.

N. Singh, M. Gupta, P. Sirohi, and . Varsha, Effects of alcoholic extract of Momordica charantia (Linn.) whole fruit powder on the pancreatic islets of alloxan diabetic albino rats, Journal of Environmental Biology, vol.29, issue.1, pp.101-107, 2008.

N. Fernandes, C. Lagishetty, V. Panda, and S. Naik, An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract -BMC Complementary and Alternative Medecine, vol.7, p.29, 2007.

N. Singh and M. Gupta, Regeneration of beta cells in islets of langerhans of pancreas of alloxan diabetic rats by acetone extract of Momordica charantia (Linn.) (bitter gourd) fruits -Indian, Journal of Experimental Biology, vol.45, issue.12, pp.1055-62, 2007.

S. Yibchok-anun, S. Adisakwattana, C. Y. Yao, P. Sangvanich, S. Roengsumran et al., Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities -Biological and Pharmaceutical Bulletin, vol.29, pp.1126-1157, 2006.

I. Ahmed, E. Adeghate, A. K. Sharma, P. Dj, and J. Singh, Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocindiabetic rat -Diabetes Research and Clinical Practice, vol.40, pp.145-51, 1998.

R. M. Hafizur, N. Kabir, and S. Chishti, Modulation of pancreatic ?-cells in neonatally streptozotocin-induced type 2 diabetic rats by the ethanolic extract of Momordica charantia fruit pulp -Natural Product Research, vol.25, pp.353-67, 2011.

G. A. Bhat, H. A. Khan, A. S. Alhomida, P. Sharma, R. Singh et al., GLP-I secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia -BMC Complementary and Alternative Medicine, vol.18, p.182, 2018.

A. Drewnowski and . Gomez-carneros, C -Bitter taste, phytonutrients, and the consumer: a review, American Journal of Clinical Nutrition, vol.72, issue.6, pp.1424-1459, 2000.

R. Fachinan, A. Fagninou, P. Nekoua, M. Amoussa, A. M. Adjagba et al., Moutairou K and Yessoufou A-Evidence of immunosuppressive and Th2 immune polarizing effects of antidiabetic Momordica charantia fruit juice, BioMed Research International, p.13, 2017.

R. Fachinan, A. Yessoufou, P. Nekoua, M. Moutairou, and K. , Effectiveness of antihyperglycemic effect of Momordica charantia: implication of T-cell cytokines -Evidence-Based Complementary and Alternative Medicine, vol.2017, p.8, 2017.

D. Sathishsekar and S. Subramanian, Antioxidant properties of Momordica charantia (bitter gourd) seeds on streptozotocin induced diabetic rats, Asia Pacific Journal of Clinical Nutrition, vol.14, issue.2, pp.153-161, 2005.

U. N. Tripathi and D. Chandra, Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Momordica charantia pulp and Trigonella foenum graecum seed in alloxan-induced diabetic rats -Indian, Journal of Biochemistry and Biophysics, vol.47, issue.4, pp.227-260, 2010.

S. S. Saha and M. Ghosh, Antioxidant and anti-inflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes, British Journal of Nutrition, vol.108, issue.6, pp.974-83, 2012.

Z. A. Malik, M. Singh, and P. L. Sharma, Neuroprotective effect of Momordica charantia in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice, Journal of Ethnopharmacology, vol.133, issue.2, pp.729-763, 2011.

D. Y. Saad, M. M. Soliman, A. A. Baiomy, Y. Mg, and . El-sawy, HB -Effects of karela (bitter melon; Momordica charantia) on genes of lipids and carbohydrates metabolism in experimental hypercholesterolemia: biochemical, molecular and histopathological study -Complementary and Alternative Medicine, vol.17, p.319, 2017.

, Qiang Ma -Role of Nrf2 in oxidative stress and toxicity -The Annual Review of Pharmacology and Toxicology, vol.53, pp.401-427, 2013.

M. Raish, Momordica charantia polysaccharides ameliorate oxidative stress, hyperlipidemia, inflammation, and apoptosis during myocardial infarction by inhibiting the NF-?B signaling pathway, International Journal of Biological Macromolecules, vol.97, pp.544-51, 2017.

D. D. Zhang, Mechanistic studies of the Nrf2-Keap1 signaling pathway, Journal Drug Metabolism Reviews, vol.38, issue.4, pp.769-89, 2006.

M. Raish, A. Ahmad, B. L. Jan, K. M. Alkharfy, M. A. Ansari et al., A -Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats, International Journal of Biological Macromolecules, vol.91, pp.394-99, 2016.

A. Agarwal and H. Nick, Renal response to tissue injury: Lessons from heme oxygenase-1 gene ablation and expression, Journal of the American Society of Nephrology, vol.11, issue.5, pp.965-73, 2000.

J. Yue, J. Xu, J. Cao, X. Zhang, and Y. Zhao, Cucurbitane triterpenoids from Momordica charantia L. and their inhibitory activity against ?-glucosidase, ?-amylase and protein tyrosine phosphatase 1B (PTP1B) -The Journal of Functional Foods, vol.37, pp.624-655, 2017.

B. W. Roffey, A. S. Atwal, T. Johns, and S. Kubow, Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells, Journal of Ethnopharmacology, vol.112, issue.1, pp.77-84, 2007.

M. F. Mahomoodally, A. Gurib-fakim, and A. H. Subratty, Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of D-glucose, Ltyrosine and fluid transport across rat everted intestinal sacs in vitro, Journal of Ethnopharmacology, vol.110, issue.2, pp.257-63, 2007.

T. Uebanso, H. Arai, Y. Taketani, M. Fukaya, H. Yamamoto et al., Extracts of Momordica charantia suppress postprandial hyperglycemia in rats, Journal of Nutritional Science and Vitaminology, vol.53, issue.6, pp.482-490, 2007.

P. Chaturvedi, Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects, Journal of Medicinal Food, vol.15, issue.2, pp.101-108, 2012.

Y. Oishi, T. Sakamoto, H. Udagawa, H. Taniguchi, K. Kobayashi-hattori et al., Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction -Bioscience, Biotechnology, and Biochemistry, vol.71, issue.3, pp.735-775, 2007.

A. Kumar-shetty, S. Kumar, G. , V. Salimath, and P. Gourd, Momordica charantia) modulates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats -Molecular Nutrition and Food Research, vol.49, pp.791-797, 2005.

M. F. Mahomoodally, A. H. Subratty, A. Gurib-fakim, M. I. Choudhary, N. Khan et al., Traditional medicinal herbs and food plants have the potential to inhibit key carbohydrate hydrolyzing enzymes in vitro and reduce postprandial blood glucose peaks in vivo, Scientific World Journal, p.285284, 2012.

H. Matsuur, C. Asakawa, M. Kurimoto, and J. Mizutani, Alpha-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa -Bioscience, Biotechnology, and Biochemistry, vol.66, issue.7, pp.1576-1584, 2002.

R. Kumar, S. Balaji, T. S. Uma, and P. K. Sehgal, Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPAR gamma and PI3K, Journal of Ethnopharmacology, vol.126, issue.3, pp.533-540, 2009.

E. Cummings, H. S. Hundal, H. Wackerhage, M. Hope, M. Belle et al., Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes -Molecular and Cellular Biochemistry, vol.261, pp.99-104, 2004.

M. G. Sridhar, R. Vinayagamoorthi, A. Suyambunathan, V. , B. Z. Selvaraj et al., Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats, British Journal of Nutrition, vol.99, issue.4, pp.806-818, 2008.

Q. Zhong, . Wang, H. Xian, Y. Zhang, A. Yu et al., Cefalu -Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet fed mice -The Journal of Nutritional Biochemistry, vol.22, pp.1064-73, 2011.

P. V. Nerurkar, Y. K. Lee, M. Motosue, A. K. Nerurkar, and V. R. , Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions, British Journal of Nutrition, vol.100, issue.4, pp.751-760, 2008.

T. Miura, C. Itoh, N. Iwamoto, M. Kato, M. Kawai et al., Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice, Journal of Nutritional Science and Vitaminology, vol.47, issue.5, pp.340-344, 2001.

J. H. Han, N. Q. Tuan, M. H. Park, K. T. Quan, J. Oh et al., Cucurbitane triterpenoids from the fruits of Momordica charantia improve insulin sensitivity and glucose homeostasis in streptozotocin-induced diabetic mice -Molecular, Nutrition Food Research, vol.62, issue.7, 2018.

C. Ma, H. Yu, X. Y. Wang, and H. , Momordica charantia extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats -Pharmaceutical Biology, vol.55, pp.2170-77, 2017.

H. L. Cheng, C. Y. Kuo, Y. W. Liao, and C. Lin, a hypoglycemic triterpene isolated from Momordica charantia wild variant, attenuates TNF-?-induced inflammation in FL83B cells in an AMP-activated protein kinase-independent manner, European Journal of Pharmacology, vol.689, issue.1-3, pp.241-249, 2012.

K. Zeng, Y. N. He, D. Yang, J. Q. Cao, X. C. Xia et al., New compounds from acid hydrolyzed products of the fruits of Momordica charantia L. and their inhibitory activity against protein tyrosine phosphatas 1B, European Journal of Medicinal Chemistry, vol.81, pp.176-80, 2014.

S. D. Klomann, A. S. Mueller, J. Pallauf, and M. B. Krawinkel, Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice, British Journal of Nutrition, vol.104, issue.11, pp.1613-1633, 2010.

N. B. Ruderman, D. Carling, M. Prentki, and J. Cacicedo, and the metabolic syndrome, J Clin InvestJournal of Clinical Investigation, vol.123, issue.7, pp.2764-72, 2013.

A. Ginion, J. Auquier, C. R. Benton, C. Mouton, J. L. Vanoverschelde et al., Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake, The American Journal of Physiology-Heart and Circulatory Physiology, vol.301, issue.2, pp.469-77, 2011.

H. L. Cheng, H. K. Huang, C. I. Chang, C. P. Tsai, and C. H. Chou, A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase, Journal of Agricultural and Food Chemistry, vol.56, issue.16, pp.6835-6878, 2008.

T. J. Iseli, N. Turner, X. Y. Zeng, G. J. Cooney, E. W. Kraegen et al., Activation of AMPK by bitter melon triterpenoids involves CaMKK? -PLoS One, vol.8, p.62309, 2013.

M. M. Yung, F. A. Ross, D. G. Hardie, T. H. Leung, J. Zhan et al., Bitter melon (Momordica charantia) extract inhibits tumorigenicity and overcomes cisplatin-resistance in ovarian cancer cells through targeting AMPK signaling cascade -Integrative Cancer Therapies, vol.15, pp.376-89, 2016.

M. F. Mccarty, Does bitter melon contain an activator of AMP-activated kinase? -Medical Hypotheses, vol.63, pp.340-343, 2004.

S. Poovitha and M. Parani, Protein extract from the fruit pulp of Momordica charantia potentiate glucose uptake by up-regulating GLUT4 and AMPK, Journal of Functional Foods, vol.37, pp.507-519, 2017.

C. Y. Chuang, C. Hsu, C. Y. Chao, Y. S. Wein, Y. H. Kuo et al., Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPAR? in bitter gourd, Momordica charantia L.) -Journal of Biomedical Science, vol.13, pp.763-72, 2006.

J. Berger and D. E. Moller, The mechanisms of action of PPARs -The Annual Review of Medicine, vol.53, pp.409-444, 2002.

G. C. Chen, H. M. Su, Y. S. Lin, P. Y. Tsou, J. H. Chyuan et al., A conjugated fatty acid present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD+/NADH ratio and activating PPAR?, AMPK and SIRT1 signaling pathway, The Journal of Nutritional Biochemistry, vol.33, pp.28-35, 2016.

C. Cantó, Z. Gerhart-hines, J. N. Feige, M. Lagouge, L. Noriega et al., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity -Nature, vol.458, pp.1056-60, 2009.

M. C. Sugden, P. W. Caton, M. Holness, and . Control, it's SIRTainly as easy as PGC -The Journal of Endocrinology, vol.204, pp.93-104, 2010.

Y. Y. Chang, H. M. Su, S. H. Chen, W. T. Hsieh, J. H. Chyuan et al., Roles of peroxisome proliferator-activated receptor ? in bitter melon seed oil-corrected lipid disorders and conversion of ?-eleostearic acid into rumenic acid in C57BL/6J mice -Nutrients, vol.8, p.805, 2016.

C. Y. Chao, C. Huang, and . Gourd, Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells, Journal of Biomedical Science, vol.10, issue.6, pp.782-91, 2003.

J. R. Weng, L. Y. Bai, and W. Y. Lin, Identification of a triterpenoid as a novel PPAR? activator derived from formosan plants -Phytotherapy Research, vol.31, pp.1722-1752, 2017.

C. C. Shih, C. H. Lin, L. Wl, and J. B. Wu, Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats, Journal of Ethnopharmacology, vol.123, issue.1, pp.82-90, 2009.

C. C. Shih, C. H. Lin, and W. L. Lin, Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet -Diabetes Research and Clinical Practice, vol.81, pp.134-177, 2008.

V. Gadang, W. Gilbert, N. Hettiararchchy, R. Horax, L. Katwa et al., Dietary bitter melon seed increases peroxisome proliferator-activated receptor-? gene expression in adipose tissue, down-regulates the nuclear factor-?B expression, and alleviates the symptoms associated with metabolic syndrome, Journal of Medicinal Food, vol.14, pp.86-93, 2011.

S. Chandru, P. Vishwanath, D. Devegowda, and S. N. Ramasamudra, Prashant A and Hathur B -Evaluation of protein kinase C? and PPAR? activity in diabetic rats supplemented with Momordica charantia, Journal of Clinical and Diagnostic Research, vol.10, issue.4, pp.1-04, 2016.

L. L. Chan, Q. Chen, A. G. Go, E. K. Lam, and E. T. Li, Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression, Journal of Nutrition, vol.135, issue.11, pp.2517-2540, 2005.

C. Y. Chao, Y. Mc, and C. J. Huang, Wild bitter gourd extract up-regulates mRNA expression of PPAR?, PPAR? and their target genes in C57BL/6J mice, Journal of Ethnopharmacology, vol.135, issue.1, pp.156-61, 2011.

H. Masuzaki, J. Paterson, H. Shinyama, N. M. Morton, J. J. Mullins et al., A transgenic model of visceral obesity and the metabolic syndrome -Science, vol.294, pp.2166-70, 2001.

N. M. Morton, J. M. Paterson, H. Masuzaki, M. C. Holmes, B. Staels et al., Novel adipose tissue-mediated resistance to dietinduced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice-Diabetes, vol.53, pp.931-939, 2004.

A. Blum, C. Loerz, H. J. Martin, C. A. Staab-weijnitz, and E. Maser, Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11?-hydroxysteroid dehydrogenase type 1 inhibitor -The Journal of Steroid Biochemistry and Molecular Biology, vol.128, pp.51-56, 2012.

H. L. Huang, Y. W. Hong, Y. H. Wong, Y. N. Chen, J. H. Chyuan et al., Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats, British Journal of Nutrition, vol.99, issue.2, pp.230-239, 2008.

S. Matsui, T. Yamane, T. Takita, Y. Oishi, and . Kobayashi-hattori, K -The hypocholesterolemic activity of Momordica charantia fruit is mediated by the altered cholesterol-and bile acid-regulating gene expression in rat liver -Nutrition Research, vol.33, pp.580-585, 2013.

I. Ahmed, M. S. Lakhani, M. Gillett, J. A. Raza, and H. , Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats -Diabetes Research and Clinical Practice, vol.51, pp.155-61, 2001.

P. Chaturvedi, S. George, M. Milinganyo, and Y. B. Tripathi, Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats -Phytotherapy Research, vol.18, pp.954-960, 2004.

C. Q. Li and E. , Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines, British Journal of Nutrition, vol.93, issue.5, pp.747-54, 2005.

P. Chaturvedi and S. George, Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load, Journal of Medicinal Dood, vol.13, issue.3, pp.520-527, 2010.

V. Gadang, W. Gilbert, N. Hettiararchchy, R. Horax, L. Katwa et al., L -Dietary bitter melon seed increases peroxisome proliferator-activated receptor-? gene expression in adipose tissue, down-regulates the nuclear factor-?B expression, and alleviates the symptoms associated with metabolic syndrome, Journal of Medicinal Food, vol.14, issue.1-2, pp.86-93, 2011.

B. Bao, Y. G. Chen, L. Zhang, N. Xu, Y. L. Wang et al., Bitter Melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues -PLoS One, vol.8, p.84075, 2013.

B. A. Shibib, L. A. Khan, and R. Rahman, Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase -The Biochemical Journal, vol.292, pp.267-70, 1993.

C. K. Lii, H. W. Chen, Y. Wt, and K. L. Liu, Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviate ser.) fruit extracts on inflammatory responses in RAW264.7 macrophages, Journal of Ethnopharmacology, vol.122, issue.2, pp.227-260, 2009.

K. Hk and K. Kim, Bitter melon (Momordica charantia) extract suppresses cytokine induced activation of MAPK and NF-?B in pancreatic ?-Cells -Food Science and Biotechnology -2011, vol.20, pp.531-566

J. Bai, Y. Zhu, and Y. Dong, Response of gut microbiota and inflammatory status to bitter melon (Momordica charantia L.) in high fat diet induced obese rats, Journal of Ethnopharmacology, vol.194, pp.717-743, 2016.

S. J. Yang, J. M. Choi, S. E. Park, E. J. Rhee, W. Y. Lee et al., Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-?B and JNK pathways in highfat-fed OLETF rats -The Journal of Nutritional Biochemistry, vol.26, pp.234-274, 2015.

C. Ma, H. Yu, X. Y. Wang, and H. , Momordica charantia extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats -Pharmaceutical Biology, vol.55, pp.2170-77, 2017.

H. C. Sung, C. W. Liu, C. Y. Hsiao, S. R. Lin, I. S. Yu et al., The effects of wild bitter gourd fruit extracts on ICAM-1 expression in pulmonary epithelial cells of C57BL/6J mice and microRNA-221/222 knockout mice: Involvement of the miR-221/-222/PI3K/AKT/ NF-?B pathway -Phytomedicine, vol.42, pp.90-99, 2018.

M. M. Ali, I. H. Borai, and H. M. Ghanem, Abdel-Halim AH and Mousa FM -The prophylactic and therapeutic effects of Momordica charantia methanol extract through controlling different hallmarks of the hepatocarcinogenesis, Biomedicine & Pharmacotherapy, vol.98, pp.491-98, 2018.

. Wh-wu, Y. H. Lin, C. J. Kuo, and . Huang, Triglycerides constituted of short and medium chain fatty acids and dicarboxylic acids in Momordica charantia, as well as capric acid, inhibit PGE2 production in RAW264.7. macrophages -Food Chemistry, vol.117, pp.306-317, 2009.

M. Manabe, R. Takenaka, T. Nakasa, and O. Okinaka, Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd) -Bioscience, Biotechnology, and Biochemistry, vol.67, issue.12, pp.2512-2519, 2003.

S. A. Shodehinde, S. A. Adefegha, G. Oboh, S. I. Oyeleye, T. A. Olasehinde et al., Adedayo BC and Boligon AA -Phenolic composition and evaluation of methanol and aqueous extracts of bitter gourd (Momordica charantia L) leaves on angiotensin-Iconverting enzyme and some pro-oxidant-induced lipid peroxidation in vitro, Sage Journals/Journal of Evidence-Based Integrative Medicine, vol.21, issue.4, pp.67-76, 2016.

A. Ceriello, Possible role of oxidative stress in the pathogenesis of hypertension -Diabetes Care, vol.31, pp.181-84, 2008.

G. Oboh and J. Rocha, foods: a new challenge for food processors. Leading Edge Antioxidants Research -Nova Science Publishers, pp.35-64, 2007.

L. Guerrero, J. Castillo, and M. Quiñones, Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies -PLoS One, vol.7, p.49493, 2012.

J. Singh, E. Cumming, G. Manoharan, H. Kalasz, and E. Adeghate, Medicinal chemistry of the anti-diabetic effects of Momordica charantia: active constituents and modes of actions -The Open, Medicinal Chemistry Journal, vol.5, issue.2, pp.70-77, 2011.

A. K. Sharma, I. Duguid, D. S. Blanchard, and P. K. Thomas, The effect of insulin treatment on myelinated nerve fibre maturation and integrity and on body growth in streptozotocin-diabetic rats, The Journal of the Neurological Sciences, vol.67, pp.285-97, 1985.

I. Ahmed, A. K. Sharma, A. S. Ponery, A. Bener, and J. Singh, The influence of Momordica charantia on ultrastructural abnormalities of myelinated fibres in experimental diabetes -The International Journal of Diabetes, vol.7, pp.110-131, 1999.

M. Cortez-navarrete, E. Martínez-abundis, K. G. Pérez-rubio, M. González-ortiz, and M. , Villar M -Momordica charantia administration improves insulin secretion in type 2 diabetes mellitus, Journal of Medicinal Food, vol.21, issue.7, pp.672-77, 2018.

S. T. Lim, A. C. Jimeno, R. Eb, M. Velasquez, and . Study, The effect of Momordica Charantia tablets on glucose and insulin levels during the postprandial state among patients with type 2 diabetes mellitus, Philippine Journal of Internal Medicine, vol.48, issue.2, pp.19-25, 2010.

V. S. Baldwa, . Bhandari, A. Pangaria, and R. K. Goyal, Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source, Upsala Journal of Medical Sciences, vol.82, pp.39-41, 1977.

P. Khanna, S. C. Jain, A. Panagariya, and V. Dixit, Journal of Natural Products, vol.44, issue.6, pp.648-55, 1981.

J. T. Efird, Y. M. Choi, S. W. Davies, S. Mehra, A. E. Katunga et al., Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes, International Journal of Environmental Research and Public Health, vol.11, issue.2, pp.2328-2373, 2014.

V. S. Baldwa, C. M. Bhandari, A. Pangaria, and R. K. Goyal, Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source -Upsala journal of medical sciences, vol.82, pp.39-41, 1977.

S. Kumari, I. Dash, and K. K. Behera, Therapeutic effect of Momordica charantia on blood glucose, lipid profile and oxidative stress in type 2 diabetes mellitus patients: A randomised controlled trial, Journal of Clinical and Diagnostic Research JCDR, vol.12, issue.9, pp.21-25, 2018.

N. Ahmad, M. R. Hassan, H. Halder, and K. S. Bennoor, Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients -Bangladesh Medical Research Council Bulletin, vol.25, pp.11-14, 1999.

W. Trakoon-osot, U. Sotanaphun, P. Phanachet, S. Porasuphatana, U. Udomsubpayakul et al., Hypoglycemic and antiglycation activities of bitter melon (Momordica charantia L.) in type 2 diabetic patients, Journal of pharmacy research, vol.6, pp.859-64, 2013.

A. Fuangchana, P. Sonthisombata, T. Seubnukarn, R. Chanouan, P. Chotchaisuwat et al., Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients, Journal of Ethnopharmacology, vol.134, issue.2, pp.422-450, 2011.

A. J. John, R. Cherian, H. S. Subhash, and A. M. Cherian, Evaluation of the efficacy of bitter gourd (Momordica charantia) as an oral hypoglycemic agent -a randomized controlled clinical trial -Indian, Journal of Physiology and Pharmacology, vol.47, issue.3, pp.363-368, 2003.

I. U. Rahman, R. U. Khan, R. Ku, and M. Bashir, Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients, Nutrition Journal, vol.14, p.13, 2015.

A. C. Suthar, A. Deshmukh, V. Babu, V. S. Mohan, M. V. Chavan et al., Efficacy and safety of glycebal (PDM011011) capsules as adjuvant therapy in subjects with type 2 diabetes mellitus : an open label, randomized, active controlled, phase II trial, Clinical Diabetology, vol.5, issue.3, pp.88-94, 2016.

A. C. Suthar, V. G. Pai, Y. Kadam, A. Tongaonkar, S. Kale et al., Efficacy and safety of PDM011011 capsules as compared to metformin in subjects with type-2 diabetes mellitus : an open-label, randomized, active-controlled, multicentric, phase III study, Journal of Diabetes Mellitus, vol.6, issue.1, pp.38-48, 2016.

A. Tongia, S. K. Tongia, and M. Dave, Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM) -Indian, Journal of Physiology and Pharmacology, vol.48, issue.2, pp.241-245, 2004.

M. Azam, C. O. Saerang, S. R. Rahayu, F. Indrawati, I. Budiono et al., A doubled-blind, crossover-RCT in T2DM for evaluating hypoglycemic effect of P. indicus, M. charantia, P. vulgaris and A. paniculata in central java, Journal of Naturel Remedies, vol.16, issue.3, 2016.

K. S. Zanker, B. Mang, M. Wolters, and A. Hahn, Personalized diabetes and cancer medicine: a rationale for anti-diabetic nutrition (bitter melon) in a supportive setting -Current Cancer Therapy Reviews, vol.8, pp.66-77, 2012.

S. May, L. Sanip, and Z. , Ahmed Shokri A, Abdul Kadir A and Md Lazin MR -The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial -Complementary Therapies in Clinical Practice, vol.32, pp.181-86, 2018.

W. Phimarn, B. Sungthong, K. Saramunee, and W. Caichompoo, Efficacy of Momordica charantia L. on blood glucose, blood lipid, and body weight: A metaanalysis of randomized controlled trials -Pharmacognosy Magazine, vol.14, pp.351-58, 2018.

E. L. Peter, F. M. Kasali, S. Deyno, A. Mtewa, P. B. Nagendrappa et al., Ogwang PE and Sesaazi D -Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis, Journal of Ethnopharmacology, vol.231, pp.311-335, 2018.

M. B. Krawinkel, C. Ludwig, M. E. Swai, R. Y. Yang, C. Kp et al., Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania, Journal of Ethnopharmacology, vol.216, pp.1-7, 2018.

M. Anas, M. Mohsin, M. Siddiqui, and A. Mannan, Therapeutic evaluation of a polyherbal formulation in type 2 diabetes mellitus, Indian Journal of Traditional Knowledge, vol.10, issue.4, pp.711-726, 2011.

C. Tsai and E. Chin-fun-chen, Hsin-Sheng Tsay and Ching-jang Huang -Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial, Nutrition Journal, vol.11, p.4, 2012.

A. R. Jadad, R. A. Moore, D. Carroll, C. Jenkinson, D. J. Reynolds et al., Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Controlled Clinical Trials, vol.17, pp.1-12, 1996.

J. T. Efird, Y. M. Choi, S. W. Davies, S. Mehra, A. E. Katunga et al., The effect of Momordica Charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies, Journal of Clinical Epidemiology, vol.60, issue.6, pp.554-563, 2007.